The tumour microenvironment in mycosis fungoides – decoupling biological and clinical responses

Clicks: 3
ID: 339136
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #415 of 415 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 415 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The tumour microenvironment (TME) plays a pivotal role in the progression of mycosis fungoides (MF), characterised by a shift in the immune response from a T helper (Th) 1 cell (Th1) to a Th2 cell profile. While this framework captures key features of disease progression, recent single-cell and spatial transcriptomic studies have further illuminated diverse malignant T-cell states, immune trajectories and spatial niches that extend beyond cytokine polarity alone. Skin-directed and systemic therapies for MF affect both malignant T-cells and the surrounding TME. The therapeutic response begins with biological changes in the TME, including tumour T-cell elimination via tumour cell killing and apoptosis, along with modification of the inflammatory milieu. Because these biological changes take time, early signs of clinical improvement may be subtle. Skin-related treatment-related adverse events, including inflammation, may occur and can be difficult to distinguish from ongoing disease. Given this overlap, careful clinical evaluation is warranted before changes to therapy are considered. It is therefore important to distinguish biological responses in the skin TME from clinical responses on the skin. In this article, we review data on biological and clinical responses to treatment in patients with MF and highlight the lack of biomarkers correlating with skin responses. Finally, we explore emerging tools and consider their potential to improve clinical decision-making when differentiating between biological and clinical responses.
Reference Key
openalex_W7225388403 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Adèle de Masson, Maxime Battistella, Emmanuella Guenova, Evangelia Papadavid, Maarten H. Vermeer, Hélène Moins‐Teisserenc
Are you one of these authors? Claim your profile
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag472
URL
https://doi.org/10.1093/bjd/ljag472
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.